Accueil › Leucémie biphénotypique aiguë › Washington › Seattle
Essais cliniques pour Leucémie biphénotypique aiguë à Seattle, WA
15 études pour Leucémie biphénotypique aiguë recherchent des participants dans et autour de Seattle (dans un rayon d'environ 30 miles). Ouvrez une étude pour voir qui peut participer et comment contacter l'équipe.
Texte officiel de l'étude (anglais)
Vous recrutez pour une étude ? Mettez-la en avant en haut de cette page — $99 pour 30 jours →
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
Recrutement en coursPhase 1
- Fred Hutchinson Cancer Center, Seattle
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
Recrutement en coursPhase 2
- Seattle Children's Hospital, Seattle
CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia
Recrutement en coursPhase 1
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Randomization for the Identification of Best Treatment Intensity for Less Fit Adults With Acute Myeloid Leukemia and Myeloid Neoplasms
Recrutement en cours
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
Recrutement en coursPhase 3
- Seattle Children's Hospital, Seattle
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
Recrutement en coursPhase 1/2
- Seattle Children's Hospital, Seattle
Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
Recrutement en coursPhase 2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer
Recrutement en coursPhase 2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia
Recrutement en coursPhase 1/2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
Recrutement en coursPhase 1/2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
Recrutement en coursPhase 2Volontaires sains bienvenus
- Fred Hutch/University of Washington Cancer Consortium, Seattle
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Recrutement en coursPhase 1
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse
Recrutement en coursPhase 1/2Volontaires sains bienvenus
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms
Recrutement en coursPhase 1/2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
Recrutement en coursPhase 1
- Seattle Children's Hospital, Seattle
Essais pour Leucémie biphénotypique aiguë dans d'autres villes
- Houston, TX11 études
- New York City, NY10 études
- Atlanta, GA9 études
- Durham, NC8 études
- Memphis, TN7 études
- Chicago, IL7 études
- Charlotte, NC6 études
- Aurora, CO6 études
- Baldwin Park, CA6 études
- Portland, OR6 études
- Los Angeles, CA6 études
- Philadelphia, PA6 études
Autres études à Seattle
- Cancer du poumon non à petites cellules53 études
- Cancer (tous types)49 études
- Cancer de la prostate42 études
- Leucémie aiguë myéloïde40 études
- Cancer du sein39 études
- Cancer métastatique39 études
- Cancer colorectal34 études
- Cancer du poumon33 études
- Cancer de l'ovaire30 études
- Myélome multiple22 études
- Syndromes myélodysplasiques21 études
- Leucémie aiguë lymphoblastique21 études
Source : ClinicalTrials.gov, données récupérées le 5 oct. 2026. Chaque étude définit ses propres critères d'éligibilité ; l'équipe de l'étude décide qui peut y participer.